AJP - Renal Physiology, Vol 258, Issue 5 1417-F1424, Copyright © 1990 by American Physiological Society

ARTICLES

Interaction of ANP and bradykinin during endopeptidase 24.11 inhibition: renal effects

G. J. Smits, D. E. McGraw and A. J. Trapani
Searle Research and Development, Chesterfield, Missouri 63198.

Experiments were performed on anesthetized rats to determine whether inhibition of endopeptidase 24.11 (EP) potentiates the biological activity of atrial natriuretic peptide, ANP-(99-126), and to examine the mechanisms that underlie this effect. Thiorphan (30 mg/kg iv), an inhibitor of EP, produced a modest increase in urinary sodium excretion when administered alone but did not affect urine flow, mean arterial pressure (MAP), or the endogenous level of plasma ANP. The infusion of ANP-(99-126) alone (67 ng.kg-1.min-1 iv) produced a modest natriuresis and decrease in MAP while increasing plasma ANP levels fivefold. When thiorphan (30 mg/kg iv) was administered during the ANP infusion, urine flow and urinary sodium excretion increased markedly but no further decrease in MAP or increase in plasma ANP levels was observed. This potentiation of the renal actions of ANP was not mediated by inhibition of angiotensin-converting enzyme, an increase in glomerular filtration rate, or an increase in renal blood flow but was completely abolished by a specific antagonist of the bradykinin receptor [( DArg0, Hyp3, Thi5, DPhe7, Thi8]bradykinin, 30 micrograms.kg-1.min-1 iv). These data suggest that inhibitors of EP can potentiate the renal activity of ANP by a mechanism which is independent of altered ANP catabolism and which may involve the accumulation of bradykinin, another substrate for EP, within the kidney.

This article has been cited by other articles:

				H. R. Croxatto, X. F. Figueroa, J. Roblero, and M. P. Boric Kinin B2 Receptors Mediate Blockade of Atrial Natriuretic Peptide Natriuresis Induced by Glucose or Feeding in Fasted Rats Hypertension, October 1, 1999; 34(4): 826 - 831. [Abstract] [Full Text] [PDF]

				A.-M. Duncan, G. M. James, F. Anastasopoulos, A. Kladis, T. A. Briscoe, and D. J. Campbell Interaction Between Neutral Endopeptidase and Angiotensin Converting Enzyme Inhibition in Rats with Myocardial Infarction: Effects on Cardiac Hypertrophy and Angiotensin and Bradykinin Peptide Levels J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 295 - 303. [Abstract] [Full Text]

				D. J. Campbell, F. Anastasopoulos, A.-M. Duncan, G. M. James, A. Kladis, and T. A. Briscoe Effects of Neutral Endopeptidase Inhibition and Combined Angiotensin Converting Enzyme and Neutral Endopeptidase Inhibition on Angiotensin and Bradykinin Peptides in Rats J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 567 - 577. [Abstract] [Full Text]

				H. Yu, O. A. Carretero, L. A. Juncos, and J. L. Garvin Biphasic Effect of Bradykinin on Rabbit Afferent Arterioles Hypertension, August 1, 1998; 32(2): 287 - 292. [Abstract] [Full Text] [PDF]

				M. P. Boric and H. R. Croxatto Inhibition of Atrial Natriuretic Peptide Excretory Action by Bradykinin Hypertension, December 1, 1995; 26(6): 1167 - 1172. [Abstract] [Full Text]

				S. Saitoh, A. G. Scicli, E. Peterson, and O. A. Carretero Effect of Inhibiting Renal Kallikrein on Prostaglandin E2, Water, and Sodium Excretion Hypertension, May 1, 1995; 25(5): 1008 - 1013. [Abstract] [Full Text]

				K. B. Margulies, P. L. Barclay, and J. C. Burnett Jr The Role of Neutral Endopeptidase in Dogs With Evolving Congestive Heart Failure Circulation, April 1, 1995; 91(7): 2036 - 2042. [Abstract] [Full Text]